Regeneron Pharmaceuticals, IncNasdaq: REGN

No material news in the last 48 hours.

No material news in the last 48 hours.

The World Health Organization's Therapeutics Advisory Group selected Regeneron's maftivimab, a component of FDA-approved Inmazeb, for evaluation in clinical trials against Bundibugyo ebolavirus, expanding the antibody's potential use. Separately, Regeneron is testing weekly Praluent dosing in a new cholesterol study and pointed to real-world Dupixent data that could extend its asthma franchise edge with Sanofi. Shares rose about 2.73% to close near $616 on June 15, 2026, though the stock remains below major moving averages. The pipeline news is incremental rather than transformational and follows a roughly 10.5% drop about two weeks earlier when the Phase 3 fianlimab/cemiplimab combination missed its progression-free survival endpoint in advanced skin cancer. The risk is that these early-stage and infectious-disease programs are small relative to Regeneron's core eye and immunology revenue, so near-term financial impact is limited. Wall Street remains broadly bullish with an average 12-month target around $827.

Regeneron Pharmaceuticals Inc (REGN) Stock Price & News - Google Financegoogle.comWhat is behind Regeneron Pharmaceuticals stock's recent gain in value todaytradersunion.comREGN: Regeneron Pharmaceuticals Inc - CNBCcnbc.com

No material news in the last 48 hours.

No material news in the last 48 hours.

Regeneron shares fell more than 11% on May 18, 2026 after the company disclosed that the Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma missed its primary endpoint versus Merck's Keytruda, a setback for what management had previously flagged as a potential blockbuster. In response, Wolfe Research lowered its price target to $860 from $900 and Evercore ISI cut to $825 from $875. On the positive side, Regeneron and Sanofi presented Phase 4 REMODEL data showing Dupixent improved esophageal function in eosinophilic esophagitis, and the company announced a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon Conjugates. Several law firms including Levi & Korsinsky and SueWallSt have opened shareholder investigations following the trial-related decline. REGN traded near $643 as of May 20, 2026.

Regeneron (REGN) Faces Significant Decline, Drops Over 11%gurufocus.comREGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticalsbusinesswire.comDupixent Demonstrates Improved Esophageal Function in EoE Phase 4 Trialinvestor.regeneron.com

Regeneron Pharmaceuticals shares plunged more than 10% at the open on May 18, 2026, after the company disclosed over the weekend that its Phase 3 melanoma trial of fianlimab combined with Libtayo failed to beat Keytruda on its primary endpoint. Citi downgraded the stock to Hold and several analysts cut price targets following the readout. Multiple law firms, including Levi & Korsinsky and SueWallSt, have launched shareholder investigations into whether Regeneron made misleading statements about the trial's expected outcome. On May 18, Regeneron also announced a $125M strategic research collaboration with Parabilis Medicines for Helicon peptide therapeutics. The company declared a $0.94 dividend with an ex-date of May 20.

Regeneron (REGN) Faces Significant Decline, Drops Over 11%gurufocus.comRegeneron inks $125M Parabilis Helicon peptide dealstocktitan.netREGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticalsprnewswire.com

In a 1,546-patient Phase 3 melanoma study, Regeneron's high-dose fianlimab combination with cemiplimab (Libtayo) extended median progression-free survival by about five months vs. Merck's Keytruda but missed statistical significance, dealing a blow to REGN's oncology strategy. Shares fell roughly 11-12% in premarket/morning trade on May 18, 2026, to around $618, with at least 10 brokerages cutting price targets - Citi downgraded to Neutral from Buy and trimmed its target to $700 from $900, and RBC Capital cut to $707, while BofA reiterated Buy with $860 and Jefferies held its Buy. Separately, Regeneron disclosed a partnership with privately held Parabilis Medicines worth up to $2.2 billion in milestone payments for hard-to-reach disease targets, and confirmed a $0.94 cash dividend with an ex-date of May 20. The combination matters because oncology was a key long-term growth pillar beyond Eylea and Dupixent, and another pipeline miss raises questions about diversification. The bear case is intensifying competitive pressure from Keytruda plus broader pipeline execution risk; the partial offset is the Parabilis deal, ongoing Dupixent strength, and a fresh $3B buyback authorized in late April.

Regeneron drops after skin cancer treatment misses late-stage trial goal - CNBCcnbc.comRegeneron Pharmaceuticals - Yahoo Financefinance.yahoo.comRegeneron (REGN) Stock Drops 11% as Melanoma Drug Fails - CoinCentralcoincentral.com

On May 18, 2026 Regeneron announced its late-stage Phase 3 trial of fianlimab (LAG-3 inhibitor) in combination for first-line unresectable/metastatic melanoma failed to beat Merck's Keytruda, sending shares down ~12%. The setback adds to a string of recent challenges and follows weaker stock performance with shares down ~7% over the past month and ~13% over three months, closing near $698.25 in mid-May. On May 8 Regeneron was named to the Dow Jones Best-in-Class World Index for the seventh consecutive year, and on May 15 the 2026 Regeneron International Science and Engineering Fair distributed $7M in student awards. Bank of America Securities reiterated Buy on May 8. Consensus from 23 analysts remains Buy with an average PT of $842.13 (implying ~17% upside) heading into the trial readout, though estimates are likely to be revised post-failure.

Regeneron Sinks After Late-Stage Melanoma Trial Failurebloomberg.comRegeneron Reports Phase 3 Trial Results for Melanoma Treatmentgurufocus.comRegeneron Named to Dow Jones Best-in-Class World Indexglobenewswire.com

Regeneron's $0.94 quarterly cash dividend goes ex-dividend on May 20, 2026. The company recently won FDA approval for Otarmeni, the first gene therapy for a rare genetic form of deafness, and is offering it free in the U.S. Regeneron struck a drug pricing agreement with the White House, gaining relief from government pricing mandates in exchange for $9B in U.S. R&D and manufacturing investment through 2030. Q1 2026 revenue grew 19% with Dupixent up 33% to $4.9B and Eylea HD up 52%. The company also authorized a new $3.0B buyback. Analyst consensus Buy with $842 target; risk: regulatory and competitive dynamics in eye-care biosimilars.

Regeneron Reports First Quarter 2026 Financial and Operating Resultsinvestor.regeneron.comDoes Regeneron's Gene Therapy Milestone and Buyback Shift the Bull Case For Regeneron Pharmaceuticals (REGN)?simplywall.stRegeneron Q1 2026 net income falls 10% to $727mpharmaceutical-technology.com

Regeneron reported in May 2026 that Dupixent (dupilumab) demonstrated improved esophageal function in eosinophilic esophagitis in a Phase 4 trial, expanding the franchise's clinical profile. Bank of America upgraded the stock citing improving fundamentals and 2026 catalysts, joining a 23-analyst Buy consensus with an $842 average price target (about 17% upside from $721). The recently FDA-approved Otarmeni gene therapy for OTOF-related hearing loss continues to gain attention as the first neurosensory gene therapy, offered free to U.S. patients. A $0.94 dividend ex-date is May 20, and the company presented at the BofA Healthcare Conference on May 12. Q1 revenue rose to $3.4-3.6 billion, up 8-19% YoY driven by Eylea HD and Dupixent. The risk is Eylea biosimilar competition and the free-of-charge launch model for Otarmeni limiting near-term revenue.

Regeneron Pharmaceuticals upgraded by Bank of Americaproactiveinvestors.comRegeneron Wins FDA Approval for First Neurosensory Gene Therapygenengnews.comIs This Biotech Stock a Buy After a Groundbreaking Approval?fool.com

On May 7, Eli Lilly and Regeneron advanced their obesity combination bet as a key tirzepatide trial reached completion - a major catalyst for the combined obesity-treatment opportunity. On May 5, Regeneron and Sanofi presented Dupixent Phase 4 trial results showing improved esophageal function in eosinophilic esophagitis. The stock has rebounded 0.93% week-over-week despite being down 7.02% over the past month following Q1 results showing revenue of $3.6B and net income of $727M. The company authorized a fresh $3B share buyback after completing $2.31B prior repurchase, and declared a $0.94 dividend (ex-date May 20). Analyst views split: Guggenheim raised PT to $995, RBC Capital lowered to $762.

Lilly and Regeneron Advance Obesity Combo Betprnewswire.comRegeneron Press Releasesnewsroom.regeneron.comDoes Regeneron Gene Therapy Milestone and Buyback Shift the Bull Case?simplywall.st

Regeneron is participating in the BofA Securities Health Care Conference 2026 on May 12, where management will discuss its pipeline of nearly 50 candidates. Bank of America issued a fresh price-target reset, reshaping the narrative around the stock as biosimilar competition for Eylea looms in H2 2026. The recently FDA-approved Otarmeni gene therapy for OTOF-related hearing loss is being offered free to U.S. patients. Dupixent posted positive Phase 4 esophageal function data in EoE. Shares trade near $721 (down ~10% over the past month) following Q1 EPS of $9.47 (5.6% beat) and revenue of $3.6B (+19% YoY). Insider Arthur Ryan disclosed share sales.

Regeneron gets Wall Street reset as BofA changes price targetthestreet.comUpcoming Events – BofA Healthcare Conference May 12investor.regeneron.comInsider Sell: Arthur Ryan Sells Shares of Regenerongurufocus.com